TGM6, a helminth secretory product, mimics TGF-β binding to TβRII to antagonize TGF-β signaling in fibroblasts

Abstract

The murine helminth parasite Heligmosomoides polygyrus expresses a family of proteins structurally related to TGF-{beta} Mimic 1 (TGM1), a secreted five domain protein that activates the TGF-{beta} pathway and converts naive T lymphocytes to immunosuppressive Tregs. TGM1 signals through the TGF-{beta} type I and type II receptors, T{beta}RI and T{beta}RII, with domains 1-2 and 3 binding T{beta}RI and T{beta}RII, respectively, and domains 4-5 binding CD44, a co-receptor abundant on T cells. TGM6 is a homologue of TGM1 that is co-expressed with TGM1, but lacks domains 1 and 2. Herein, we show that TGM6 binds T{beta}RII through domain 3, but does not bind T{beta}RI, or other type I or type II receptors of the TGF-{beta} family. In TGF-{beta} reporter assays in fibroblasts, TGM6, but not truncated TGM6 lacking domains 4 and 5, potently inhibits TGF-{beta}- and TGM1-induced signaling, consistent with its ability to bind T{beta}RII but not T{beta}RI or other receptors of the TGF-{beta} family. However, TGM6 does not bind CD44 and is unable to inhibit TGF-{beta} and TGM1 signaling in T cells. To understand how TGM6 binds T{beta}RII, the X-ray crystal structure of the TGM6 domain 3 bound to T{beta}RII was determined at 1.4 [A]. This showed that TGM6 domain 3 binds T{beta}RII through an interface remarkably similar to the TGF-{beta}:T{beta}RII interface. These results suggest that TGM6 has adapted its domain structure and sequence to mimic TGF-{beta} binding to T{beta}RII and function as a potent TGF-{beta} and TGM1 antagonist in fibroblasts. The coexpression of TGM6, along with the immunosuppressive TGMs that activate the TGF-{beta} pathway, may prevent tissue damage caused by the parasite as it progresses through its life cycle from the intestinal lumen to submucosal tissues and back again.